Eben Tessari Sells 138,614 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock

Key Points

• Eben Tessari, COO of Kiniksa Pharmaceuticals, sold 138,614 shares on August 5th for nearly $4.6 million, reducing his ownership by 73.52% to 49,915 shares.
• Kiniksa Pharmaceuticals reported earnings of $0.23 per share for the last quarter, exceeding analyst expectations of $0.18, with revenues of $156.80 million.
• Equities analysts have expressed optimism about Kiniksa's stock, with upgrades from Jefferies and Wells Fargo, now setting price targets as high as $54.00.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 138,614 shares of the company's stock in a transaction dated Tuesday, August 5th. The shares were sold at an average price of $33.20, for a total transaction of $4,601,984.80. Following the completion of the sale, the chief operating officer directly owned 49,915 shares in the company, valued at $1,657,178. This trade represents a 73.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Eben Tessari also recently made the following trade(s):

• On Monday, July 14th, Eben Tessari sold 18,900 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $28.72, for a total transaction of $542,808.00.
• On Monday, June 16th, Eben Tessari sold 17,300 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $28.28, for a total transaction of $489,244.00.
• On Wednesday, June 11th, Eben Tessari sold 45,042 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $30.51, for a total transaction of $1,374,231.42.
• On Monday, June 9th, Eben Tessari sold 10,319 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $30.38, for a total transaction of $313,491.22.
• On Tuesday, June 10th, Eben Tessari sold 15,506 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $30.46, for a total transaction of $472,312.76.
• On Monday, May 19th, Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $26.41, for a total transaction of $316,920.00.

Kiniksa Pharmaceuticals International Trading Up 1.1%

NASDAQ KNSA traded up $0.36 on Monday, hitting $32.51. 27,951 shares of the company were exchanged, compared to its average volume of 697,536. The firm has a 50 day moving average of $28.95 and a two-hundred day moving average of $24.63. The company has a market cap of $2.41 billion, a P/E ratio of 813.08 and a beta of 0.14. Kiniksa Pharmaceuticals International, plc has a 1-year low of $17.82 and a 1-year high of $33.98.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. The company had revenue of $156.80 million for the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Research analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Institutional Trading of Kiniksa Pharmaceuticals International

Large investors have recently bought and sold shares of the business. Corebridge Financial Inc. grew its stake in shares of Kiniksa Pharmaceuticals International by 3.6% during the 1st quarter. Corebridge Financial Inc. now owns 15,979 shares of the company's stock worth $355,000 after acquiring an additional 549 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 84.8% during the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after acquiring an additional 568 shares in the last quarter. Sound View Wealth Advisors Group LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 4.0% in the first quarter. Sound View Wealth Advisors Group LLC now owns 14,657 shares of the company's stock valued at $326,000 after buying an additional 568 shares in the last quarter. Martingale Asset Management L P grew its stake in shares of Kiniksa Pharmaceuticals International by 1.3% in the first quarter. Martingale Asset Management L P now owns 50,000 shares of the company's stock valued at $1,111,000 after buying an additional 640 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Kiniksa Pharmaceuticals International by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company's stock valued at $507,000 after buying an additional 1,002 shares in the last quarter. 53.95% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on KNSA. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 2nd. Wedbush reaffirmed an "outperform" rating and issued a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Wells Fargo & Company raised their target price on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a report on Wednesday, July 9th. Finally, Jefferies Financial Group raised their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a report on Tuesday, July 29th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $41.17.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.